Metformin causes G1-phase arrest via down-regulation of MIR-221 and enhances TRAIL sensitivity through DR5 up-regulation in pancreatic cancer cells

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Tanaka, Ryoichi ^a   Tomosugi, Mitsuhiro ^a   Horinaka, Mano ^a   Sowa, Yoshihiro ^a   Sakai, Toshiyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE; DEATH RECEPTOR 5; METFORMIN; MICRORNA 221; PROTEIN P27; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS REGULATORY PROTEIN; BCL2L11 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MEMBRANE PROTEIN; MICRORNA; MIRN221 MICRORNA, HUMAN; ONCOPROTEIN; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; PANCREATIC CANCER CELL LINE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-LIKE PROTEIN 11; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MEMBRANE PROTEINS; METFORMIN; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84942032851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125779     Document Type: Article

References (42)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29. doi: 10. 3322/caac.21208 PMID: 24399786
2. Kleger A, Perkhofer L, Seufferlein T. Smarter drugs emerging in pancreatic cancer therapy. Ann Oncol. 2014;25:1260-1270. doi: 10.1093/annonc/mdu013 PMID: 24631947
3. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825. doi: 10.1056/NEJMoa1011923 PMID: 21561347
4. Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. PLoS One. 2013;8:e57528. doi: 10.1371/journal.pone.0057528 PMID: 23472089
5. Gottlieb B, Auld WH. Metformin in treatment of diabetes mellitus. Br Med J. 1962;1:680-682. PMID: 13900753
6. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602-613. doi: 10.7326/0003-4819-154-9-201105030-00336 PMID: 21403054
7. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620-1625. doi: 10.2337/dc08-2175 PMID: 19564453
8. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, et al. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013;71:63-72. doi: 10.1007/s00280-012-1977-9 PMID: 23053261
9. MacKenzie MJ, Ernst S, Johnson C, Winquist E. A phase I study of temsirolimus and metformin in advanced solid tumours. Invest New Drugs.2012;30:647-652. doi: 10.1007/s10637-010-9570-8 PMID: 20978924
10. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310:1642-1646. PMID: 16308421
11. Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;15:1695-1700.
12. Bednar F, Simeone DM. Metformin and cancer stem cells: old drug, new targets. Cancer Prev Res. 2012;5:351-354. doi: 10.1158/1940-6207. CAPR-12-0026 PMID: 22389436
13. Choi YK, Park KG. Metabolic roles of AMPK and metformin in cancer cells. Mol Cells. 2013;36:279-287. doi: 10.1007/s10059-013-0169-8 PMID: 23794020
14. Li W, Yuan Y, Huang L, Qiao M, Zhang Y. Metformin alters the expression profiles of microRNAs in human pancreatic cancer cells. Diabetes Res Clin Pract. 2012;96:187-195. doi: 10.1016/j.diabres. 2011.12.028 PMID: 22245693
15. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, et al. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res. 2012;5:355-364. doi: 10.1158/1940-6207. CAPR-11-0299 PMID: 22086681
16. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576-3586. doi: 10.1038/sj.onc.1211024 PMID: 18212742
17. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-163. PMID: 9930862
18. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162. PMID: 10411544
19. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med. 2001;7:383-385. PMID: 11283636
20. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010, 28:2839-2846. doi: 10.1200/JCO.2009.25.1991 PMID: 20458040
21. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997;277:815-818. PMID: 9242610
22. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-821. PMID: 9242611
23. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997;16:5386-5397. PMID: 9311998
24. Ozawa F, Friess H, Kleeff J, Xu ZW, Zimmermann A, Sheikh MS, et al. Effects and expression of TRAIL and its apoptosis-promoting receptors in human pancreatic cancer. Cancer Lett. 2001;163:71-81. PMID: 11163110
25. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, et al. Nuclear factorkappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther. 2006;5:2251-2260. PMID: 16985059
26. Lu T, Shao N, Ji C. Targeting microRNAs to modulate TRAIL-induced apoptosis of cancer cells. Cancer Gene Ther. 2013;20:33-37. doi: 10.1038/cgt.2012.81 PMID: 23138871
27. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259-269. PMID: 16557279
28. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008;27:3845-3855. doi: 10.1038/onc.2008.6 PMID: 18246122
29. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16:498-509. doi: 10.1016/j.ccr.2009.10.014 PMID: 19962668
30. Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, et al. miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 2012;31:634-642. doi: 10.1038/onc.2011.260 PMID: 21706050
31. Wang H, Xu C, Kong X, Li X, Kong X, Wang Y, et al. Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One. 2014;9:e99067. doi: 10.1371/journal.pone.0099067 PMID: 24905916
32. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120:1046-1054. PMID: 17149698
33. Coleman CB, Lightell DJ Jr, Moss SC, Bates M, Parrino PE, Woods TC, et al. Elevation of miR-221 and -222 in the internal mammary arteries of diabetic subjects and normalization with metformin. Mol Cell Endocrinol. 2013;374:125-129. doi: 10.1016/j.mce.2013.04.019 PMID: 23648338
34. Truong Do M, Gyun Kim H, Ho Choi J, Gwang Jeong H. Metformin induces microRNA-34a to downregulate the Sirt1/Pgc-1α/Nrf2 pathway, leading to increased susceptibility of wild-type p53 cancer cells to oxidative stress and therapeutic agents. Free Radic Biol Med. 2014;74:21-34. doi: 10.1016/j. freeradbiomed.2014.06.010 PMID: 24970682
35. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878. PMID: 8069852
36. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331. PMID: 9039259
37. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009;38:e190-199. doi: 10.1097/MPA.0b013e3181ba82e1 PMID: 19730150
38. Sarkar S, Dubaybo H, Ali S, Goncalves P, Kollepara SL, Sethi S, et al. Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27kip1, p57kip2, and PUMA. Am J Cancer Res. 2013;3:465-477. PMID: 24224124
39. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26:3699-3708. PMID: 17627278
40. Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle. 2012;11:1374-1382. doi: 10.4161/cc.19798 PMID: 22421144
41. Abayasiriwardana KS, Barbone D, Kim KU, Vivo C, Lee KK, Dansen TB, et al. Malignant mesothelioma cells are rapidly sensitized to TRAIL-induced apoptosis by low-dose anisomycin via Bim. Mol Cancer Ther. 2007;6:2766-2776. PMID: 17938269
42. Gritti M, Würth R, Angelini M, Barbieri F, Peretti M, Pizzi E, et al. Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current. Oncotarget. 2014;5:11252-11268. PMID: 25361004